Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11858915 Polo like kinase 4 inhibitors

Patent 11858915 was granted and assigned to ORIC Pharmaceuticals on January, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

ORIC Pharmaceuticals

0

Current Assignee

ORIC Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Kejia Wu0

Joanne Tan0

Stephane Ciblat0

Jae Hyuk Chang0

Chudi Ndubaku0

Dilan Emine Polat0

Daniel Gordon Michael Shore0

F. Anthony Romero0

...

Date of Patent

January 2, 2024

0

Patent Application Number

183084410

Date Filed

April 27, 2023

0

Patent Citations

US Patent 9139563 Kinase inhibitors and method of treating cancer

0

US Patent 9402828 Methods of targeting PTEN mutant diseases and compositions therefor

0

US Patent 9579327 Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3′-indolin]-2′-ones

0

US Patent 9642856 Treatment for pancreatic cancer

0

US Patent 9796703 Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3′-indolin]-2′-ones

0

US Patent 9907800 Kinase inhibitors and method of treating cancer

0

US Patent 10077255 Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3′-indolin]-2′-ones

0

US Patent RE47731 Kinase inhibitors and method of treating cancer with same

0

...

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11858915 Polo like kinase 4 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.